Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Tokyo Gov't Preparing for Switch to New Drug Manufacturing/Marketing System
February 14, 2005
- Opinions Invited on Changes in Fees for Regulatory Procedures
February 14, 2005
- REGULATORY NEWS IN BRIEF
February 14, 2005
- MEETING
February 14, 2005
- Failure to Act Damaging Weak Sector: Mr Mitchum of EFPIA Japan
February 14, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 14, 2005
- DIAGNOSTIC NEWS IN BRIEF
February 14, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 14, 2005
- Preparations for Merger Going Smoothly: Mr Miyatake of Dainippon
February 14, 2005
- PRESS SEMINAR
February 14, 2005
- Sumitomo Sets Up Merger Subcommittees
February 14, 2005
- BULLETIN
February 14, 2005
- BUSINESS NEWS IN BRIEF
February 14, 2005
- Astellas to Start Out with 16,500 Employees Worldwide
February 14, 2005
- WEBSITE NEWS
February 14, 2005
- 1st 3Qtrs Business Results -1-
February 14, 2005
- 1st 3Qtrs Business Results -2-
February 14, 2005
- Annual Business Results
February 14, 2005
- Semiannual Business Results
February 14, 2005
- BULLETIN
February 7, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…